Halozyme Therapeutics (HALO) Other Operating Expenses (2010 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Other Operating Expenses of $108.8 million for Q1 2026, up 64.36% year-over-year from $66.2 million in Q1 2025, and down 75.04% quarter-over-quarter from $435.7 million in Q4 2025.
Halozyme Therapeutics (HALO) Other Operating Expenses (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Other Operating Expenses for 17 consecutive years, with $108.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Operating Expenses rose 64.36% year-over-year to $108.8 million; the TTM figure through Mar 2026 stood at $681.6 million (up 172.06% YoY), while the FY2025 annual figure was $639.0 million, up 177.27% from the prior year.
- Other Operating Expenses slipped to $108.8 million in Q1 2026 per HALO's latest filing, from $435.7 million in the prior quarter.
- Across five years, Other Operating Expenses topped out at $435.7 million in Q4 2025 and bottomed at $15.9 million in Q1 2022.
- Historically, Other Operating Expenses has averaged $83.9 million across 5 years, with a median of $66.2 million in 2025.
- Annual changes were most pronounced in 2024 — Other Operating Expenses fell 15.52% — and 2025, when it soared 628.44%.
- Halozyme Therapeutics' Other Operating Expenses stood at $46.7 million in 2022, then jumped by 50.11% to $70.1 million in 2023, then decreased by 14.62% to $59.8 million in 2024, then jumped by 628.44% to $435.7 million in 2025, then tumbled by 75.04% to $108.8 million in 2026.
- Business Quant data shows HALO's Other Operating Expenses at $108.8 million in Q1 2026, $435.7 million in Q4 2025, and $73.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 108.68 Mn |
| Mar 31, 2026 | 108.75 Mn |
| Dec 31, 2025 | 435.73 Mn |
| Sep 30, 2025 | 73.00 Mn |
| Jun 30, 2025 | 64.12 Mn |
| Mar 31, 2025 | 66.17 Mn |
| Dec 31, 2024 | 59.82 Mn |
| Sep 30, 2024 | 67.19 Mn |
| Jun 30, 2024 | 57.37 Mn |
| Mar 31, 2024 | 46.09 Mn |
| Dec 31, 2023 | 70.06 Mn |
| Sep 30, 2023 | 75.16 Mn |
| Jun 30, 2023 | 67.91 Mn |
| Mar 31, 2023 | 53.01 Mn |
| Dec 31, 2022 | 46.67 Mn |
| Sep 30, 2022 | 74.51 Mn |
| Jun 30, 2022 | 45.35 Mn |
| Mar 31, 2022 | 15.92 Mn |
| Dec 31, 2021 | 21.59 Mn |
| Sep 30, 2021 | 18.59 Mn |